Rivaroxaban improves patency and decreases inflammation in a mouse model of catheter thrombosis. Issue 144 (August 2016)

• Record Type: Journal Article
• Authors: Terry, Christi M.; He, Yuxia; Cheung, Alfred K.
• Is Part Of: Thrombosis research. Issue 144(2016)
• Page Start: 106
• Page End: 112
• Publication Date: 2016-08
• Subjects: RIVA rivaroxaban -- CVC central venous catheter -- MCP-1 monocyte chemotactic protein-1 -- MMP-9 matrix metalloproteinase-9 -- DVT deep vein thrombosis -- LMWH low-molecular weight heparin -- INR international normalized ratio -- EJV external jugular vein -- ELISA enzyme-linked immunosorbent assay; Central venous catheters -- Chemokine CCL2 -- Inflammation -- Rivaroxaban -- Venous thrombosis; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2016.06.008
• Languages: English
• ISSNs: 0049-3848

Abstract

Abstract: Introduction: Dysfunction of indwelling central venous catheters (CVC) due to tissue ingrowth or clotting is common. The study objective was to determine if the oral anticoagulant rivaroxaban (RIVA) improved CVC patency and inflammation in mice. Materials and methods: Polyurethane catheters (0.5 cm length) were placed unilaterally into the external jugular vein (EJV) of mice, which subsequently underwent daily gavage with either vehicle or RIVA (5 mg/kg). CVC patency, as assessed by B-mode and Doppler ultrasound, and hematocrit were measured at 3, 7, 14 or 21 days ( n = 8–11 mice/group/time-point). Plasma monocyte chemotactic protein-1 (MCP-1) levels were assessed by ELISA, EJV matrix metalloproteinase-9 (MMP-9) levels by western immunoblotting, and cell proliferation (anti-Ki67), macrophage infiltration (anti-MAC387) by immunostaining of EJV tissues. Results and conclusions: CVC patency was significantly improved in RIVA-treated mice compared to vehicle-treated (93.8% vs. 62.9%) with the probability of patency in RIVA-treated mice being 1.5 times that in vehicle-treated (relative risk [RR], 1.50, 95% confidence interval [CI], 1.14–1.95, p = 0.002). Plasma MCP-1 levels were lower in RIVA-treated mice vs. vehicle-treated at 21 days (389 ± 260 vs. 804 ± 292 ng/mL, p = 0.005). Cell proliferation was less at day 7 in EJV from the RIVA-treated mice than vehicle-treated (5.0% ± 3.0 vs. 11.5% ± 3.6, p = 0.0006), as were MMP-9 protein levels. There were no differences in hematocrit between vehicle and RIVA-treated groups at any time point. In conclusion, these data indicate RIVA lowers inflammation and improves CVC patency in a mouse model, supporting future studies to assess RIVA for improving CVC patency in patients. Highlights: Thrombotic complications are common with the use of central venous catheters (CVC). Warfarin and LMWH have drawbacks and uncertain benefits for preventing CVC thrombosis. Rivaroxaban has fewer drug and diet interactions and does not require therapeutic monitoring. Rivaroxaban improved patency and decreased inflammation in a mouse model of CVC thrombosis.